{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,11]],"date-time":"2026-09-11T15:08:55Z","timestamp":1789139335868,"version":"build-2803163510"},"reference-count":90,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,9,11]],"date-time":"2026-09-11T00:00:00Z","timestamp":1789084800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Pharmacol."],"abstract":"<jats:p>Preemptive pharmacogenetics (PGx) testing, which leverages genetic variation to predict drug response and toxicity, represents a pivotal advancement in precision medicine. By predicting drug-gene interactions and guiding precision dosing, it demonstrates significant potential to enhance drug safety and efficacy. However, its integration into routine clinical practice still faces a substantial translational gap. This review examines preemptive PGx testing implementation through an implementation science lens, moving beyond clinical utility to synthesize the implementation landscape and identify systemic integration challenges. Over the past decade, a growing body of pragmatic implementation studies has systematically cataloged barriers and facilitators across multiple levels. Adoption metrics are now relatively well-documented, however, evidence on fidelity and long-term sustainability remains scarce, and most cost-effectiveness data derive from modeling rather than implementation trials. Successful implementation of preemptive PGx testing requires synergistic strategies across multiple domains, generating robust evidence through large-scale pragmatic trials, building health informatics infrastructure, and establishing multidisciplinary service. Critical to this transformation are standardized clinical workflows, comprehensive education for healthcare providers and patients, and active participation in collaborative networks to accelerate knowledge sharing. A persistent equity gap remains that nearly all published preemptive PGx implementation programs originate from high-income countries, underscoring the urgent need for context-adapted approaches in low- and middle-income settings. Emerging implementation frameworks might offer practical guidance for embedding equity into implementation design. This paradigm shift necessitates coordinated efforts from multi-stakeholders to bridge the translational gap, ultimately enabling equitable and sustainable PGx implementation across diverse healthcare settings.<\/jats:p>","DOI":"10.3389\/fphar.2026.1906466","type":"journal-article","created":{"date-parts":[[2026,9,11]],"date-time":"2026-09-11T14:16:28Z","timestamp":1789136188000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["Implementation of preemptive pharmacogenetic testing: progress, puzzles and priorities from an implementation science perspective"],"prefix":"10.3389","volume":"17","author":[{"given":"Rong","family":"Hu","sequence":"first","affiliation":[{"name":"Department of Hematology\/Oncology, Fujian Children\u2019s Hospital (Fujian Branch of Shanghai Children\u2019s Medical Center)","place":["Fuzhou, China"]},{"name":"Department of Pharmacy, Fujian Children\u2019s Hospital (Fujian Branch of Shanghai Children\u2019s Medical Center)","place":["Fuzhou, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kaizhi","family":"Weng","sequence":"additional","affiliation":[{"name":"Department of Pediatric Hematology, Rheumatology and Nephrology, Zhangzhou Affiliated Hospital of Fujian Medical University","place":["Zhangzhou, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Biyun","family":"Guo","sequence":"additional","affiliation":[{"name":"Department of Pediatrics, The First Affiliated Hospital of Xiamen University","place":["Xiamen, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shuquan","family":"Zhuang","sequence":"additional","affiliation":[{"name":"Department of Pediatrics, Quanzhou First Hospital","place":["Quanzhou, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Junli","family":"Zhou","sequence":"additional","affiliation":[{"name":"Department of Cardiovascular Medicine and Hematology, Xiamen Children\u2019s Hospital (Xiamen Branch of Children\u2019s Hospital of Fudan University)","place":["Xiamen, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhiming","family":"Hong","sequence":"additional","affiliation":[{"name":"Department of Pediatrics, Quanzhou Children\u2019s Hospital","place":["Quanzhou, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ping","family":"Lin","sequence":"additional","affiliation":[{"name":"Department of Hematology\/Oncology, Fujian Children\u2019s Hospital (Fujian Branch of Shanghai Children\u2019s Medical Center)","place":["Fuzhou, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chunping","family":"Wu","sequence":"additional","affiliation":[{"name":"Department of Pediatric Hematology, Fujian Institute of Hematology, Fujian Provincial Key Laboratory on Hematology, Fujian Medical University Union Hospital","place":["Fuzhou, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhiyuan","family":"Chen","sequence":"additional","affiliation":[{"name":"Department of Pediatric Hematology, Rheumatology and Nephrology, Zhangzhou Affiliated Hospital of Fujian Medical University","place":["Zhangzhou, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yue","family":"Wang","sequence":"additional","affiliation":[{"name":"Department of Pediatrics, The First Affiliated Hospital of Xiamen University","place":["Xiamen, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaofang","family":"Wang","sequence":"additional","affiliation":[{"name":"Department of Pediatrics, Quanzhou First Hospital","place":["Quanzhou, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Huiyan","family":"Huang","sequence":"additional","affiliation":[{"name":"Department of Pediatrics, Quanzhou Children\u2019s Hospital","place":["Quanzhou, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hui","family":"Zhang","sequence":"additional","affiliation":[{"name":"Department of Hematology\/Oncology, Fujian Children\u2019s Hospital (Fujian Branch of Shanghai Children\u2019s Medical Center)","place":["Fuzhou, China"]},{"name":"Department of Pediatrics, The Chinese University of Hong Kong","place":["Hong Kong, Hong Kong SAR, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hao","family":"Zheng","sequence":"additional","affiliation":[{"name":"Department of Pediatric Hematology, Fujian Institute of Hematology, Fujian Provincial Key Laboratory on Hematology, Fujian Medical University Union Hospital","place":["Fuzhou, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yingyi","family":"He","sequence":"additional","affiliation":[{"name":"Department of Hematology\/Oncology, Fujian Children\u2019s Hospital (Fujian Branch of Shanghai Children\u2019s Medical Center)","place":["Fuzhou, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,9,11]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"e70144","DOI":"10.1111\/cts.70144","article-title":"Informing implementation strategies for pharmacogenomics in cancer: Development of survey tools for healthcare professionals and consumers","volume":"18","author":"Alexander","year":"2025","journal-title":"Clin. Transl. Sci."},{"key":"B2","doi-asserted-by":"publisher","first-page":"210","DOI":"10.1002\/cpt.911","article-title":"Clinical pharmacogenetics implementation consortium (CPIC) guideline for dihydropyrimidine dehydrogenase genotype and fluoropyrimidine dosing: 2017 update","volume":"103","author":"Amstutz","year":"2018","journal-title":"Clin. Pharmacol. Ther."},{"key":"B3","doi-asserted-by":"publisher","first-page":"406","DOI":"10.1161\/CIRCGEN.120.002961","article-title":"Moving genomics to routine care: an initial pilot in acute cardiovascular disease","volume":"13","author":"Aryan","year":"2020","journal-title":"Circ. Genom Precis. Med."},{"key":"B4","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1186\/s13012-017-0605-9","article-title":"A guide to using the theoretical Domains Framework of behaviour change to investigate implementation problems","volume":"12","author":"Atkins","year":"2017","journal-title":"Implement Sci."},{"key":"B5","doi-asserted-by":"publisher","first-page":"4863","DOI":"10.2147\/JMDH.S458564","article-title":"One step ahead in realizing pharmacogenetics in Low- and middle-income countries: what should we do?","volume":"17","author":"Ausi","year":"2024","journal-title":"J. Multidiscip. Healthc."},{"key":"B6","doi-asserted-by":"publisher","first-page":"4297","DOI":"10.1111\/bcp.15181","article-title":"Pharmacogenomic testing in paediatrics: clinical implementation strategies","volume":"88","author":"Barker","year":"2022","journal-title":"Br. J. Clin. Pharmacol."},{"key":"B7","doi-asserted-by":"publisher","first-page":"1364221","DOI":"10.3389\/fpubh.2024.1364221","article-title":"Forging the path to precision medicine in Qatar: a public health perspective on pharmacogenomics initiatives","volume":"12","author":"Bastaki","year":"2024","journal-title":"Front. Public Health"},{"key":"B8","doi-asserted-by":"publisher","first-page":"759","DOI":"10.1377\/hlthaff.27.3.759","article-title":"The triple aim: care, health, and cost","volume":"27","author":"Berwick","year":"2008","journal-title":"Health Aff. (Millwood)"},{"key":"B9","doi-asserted-by":"publisher","first-page":"e0268534","DOI":"10.1371\/journal.pone.0268534","article-title":"Pharmacogenomics decision support in the U-PGx project: results and advice from clinical implementation across seven European countries","volume":"17","author":"Blagec","year":"2022","journal-title":"PLoS One"},{"key":"B10","doi-asserted-by":"publisher","first-page":"19","DOI":"10.2147\/PGPM.S490135","article-title":"Pharmacogenomics tools for precision public health and lessons for Low- and middle-income countries: a scoping review","volume":"18","author":"Borb\u00f3n","year":"2025","journal-title":"Pharmgenomics Pers. Med."},{"key":"B11","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1097\/FPC.0000000000000362","article-title":"Assessment of provider-perceived barriers to clinical use of pharmacogenomics during participation in an institutional implementation study","volume":"29","author":"Borden","year":"2019","journal-title":"Pharmacogenet Genomics"},{"key":"B12","doi-asserted-by":"publisher","first-page":"ooae101","DOI":"10.1093\/jamiaopen\/ooae101","article-title":"Barriers and facilitators of the use of clinical informatics resources to facilitate pharmacogenomic implementation in resource-limited settings","volume":"7","author":"Bosic-Reiniger","year":"2024","journal-title":"JAMIA Open"},{"key":"B13","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1002\/cpt.2903","article-title":"Clinical pharmacogenetics implementation consortium (CPIC) guideline for CYP2D6, CYP2C19, CYP2B6, SLC6A4, and HTR2A genotypes and serotonin reuptake inhibitor antidepressants","volume":"114","author":"Bousman","year":"2023","journal-title":"Clin. Pharmacol. Ther."},{"key":"B14","doi-asserted-by":"publisher","first-page":"162","DOI":"10.1055\/a-0975-9595","article-title":"Clinical utilization of pharmacogenetics in psychiatry - perspectives of pharmacists, genetic counselors, implementation science, Clinicians, and industry","volume":"53","author":"Brown","year":"2020","journal-title":"Pharmacopsychiatry"},{"key":"B15","doi-asserted-by":"publisher","first-page":"1594","DOI":"10.3233\/SHTI251118","article-title":"EHR-based CDS tools supporting long-term implementation of pharmacogenomics","volume":"329","author":"Caraballo","year":"2025","journal-title":"Stud. Health Technol. Inf."},{"key":"B16","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1097\/FPC.0000000000000547","article-title":"The pharmacogenomics global research network implementation working group: global collaboration to advance pharmacogenetic implementation","volume":"35","author":"Cavallari","year":"2025","journal-title":"Pharmacogenet Genomics"},{"key":"B17","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1038\/s41397-024-00326-1","article-title":"A review of real-world evidence on preemptive pharmacogenomic testing for preventing adverse drug reactions: a reality for future health care","volume":"24","author":"Chenchula","year":"2024","journal-title":"Pharmacogenomics J."},{"key":"B18","volume-title":"CPIC Guidelines","year":"2026"},{"key":"B19","doi-asserted-by":"publisher","first-page":"e2110446","DOI":"10.1001\/jamanetworkopen.2021.10446","article-title":"Assessment of the implementation of pharmacogenomic testing in a pediatric tertiary care setting","volume":"4","author":"Cohn","year":"2021","journal-title":"JAMA Netw. Open"},{"key":"B20","doi-asserted-by":"publisher","first-page":"223","DOI":"10.1080\/14622416.2025.2539061","article-title":"From bench to bedside: a spotlight on pharmacogenomics at nemours Children's health","volume":"26","author":"Cook","year":"2025","journal-title":"Pharmacogenomics"},{"key":"B21","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1038\/s41397-024-00356-9","article-title":"Implementation of pharmacogenetic testing in pediatric oncology: barriers and facilitators assessment at eight Canadian academic health centres","volume":"24","author":"Cooper","year":"2024","journal-title":"Pharmacogenomics J."},{"key":"B22","doi-asserted-by":"publisher","first-page":"50","DOI":"10.1186\/1748-5908-4-50","article-title":"Fostering implementation of health services research findings into practice: a consolidated framework for advancing implementation science","volume":"4","author":"Damschroder","year":"2009","journal-title":"Implement Sci."},{"key":"B23","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1186\/s13012-022-01245-0","article-title":"The updated consolidated framework for implementation research based on user feedback","volume":"17","author":"Damschroder","year":"2022","journal-title":"Implement Sci."},{"key":"B24","doi-asserted-by":"publisher","first-page":"503","DOI":"10.1177\/1049731509335569","article-title":"Applying diffusion of innovation theory to intervention development","volume":"19","author":"Dearing","year":"2009","journal-title":"Res. Soc. Work Pract."},{"key":"B25","doi-asserted-by":"publisher","first-page":"1121","DOI":"10.2217\/pgs-2021-0089","article-title":"Evaluation of the veterans affairs pharmacogenomic testing for veterans (PHASER) clinical program at initial test sites","volume":"22","author":"Dong","year":"2021","journal-title":"Pharmacogenomics"},{"key":"B26","doi-asserted-by":"publisher","first-page":"1345","DOI":"10.2217\/pgs-2018-0130","article-title":"Implementing a personalized medicine program in a community health system","volume":"19","author":"Dressler","year":"2018","journal-title":"Pharmacogenomics"},{"key":"B27","doi-asserted-by":"publisher","first-page":"2335","DOI":"10.1038\/s41436-021-01269-9","article-title":"Multisite investigation of strategies for the clinical implementation of pre-emptive pharmacogenetic testing","volume":"23","author":"Duarte","year":"2021","journal-title":"Genet. Med."},{"key":"B28","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/1748-5908-1-1","article-title":"Welcome to implementation science","volume":"1","author":"Eccles","year":"2006","journal-title":"Implement Sci."},{"key":"B29","doi-asserted-by":"publisher","first-page":"377","DOI":"10.1080\/14622416.2024.2382078","article-title":"Implementing pharmacogenomic testing in Australian general practice: an exploratory qualitative study","volume":"25","author":"Ewasiuk","year":"2024","journal-title":"Pharmacogenomics"},{"key":"B30","doi-asserted-by":"publisher","first-page":"243","DOI":"10.1038\/s41591-021-01672-4","article-title":"A roadmap to increase diversity in genomic studies","volume":"28","author":"Fatumo","year":"2022","journal-title":"Nat. Med."},{"key":"B31","doi-asserted-by":"publisher","first-page":"2700","DOI":"10.1111\/cts.13664","article-title":"Patient and healthcare professional acceptability of pharmacogenetic screening for DPYD and UGT1A1: a cross sectional survey","volume":"16","author":"Glewis","year":"2023","journal-title":"Clin. Transl. Sci."},{"key":"B32","doi-asserted-by":"publisher","first-page":"803","DOI":"10.1002\/cpt.3749","article-title":"Pharmacogenetic implementation studies-lessons learned from the PREPARE study","volume":"118","author":"Guchelaar","year":"2025","journal-title":"Clin. Pharmacol. Ther."},{"key":"B33","doi-asserted-by":"publisher","first-page":"1658616","DOI":"10.3389\/fphar.2025.1658616","article-title":"Persistent benefit of pharmacogenomic testing on initial remission and response rates in patients with major depressive disorder","volume":"16","author":"Hain","year":"2025","journal-title":"Front. Pharmacol."},{"key":"B34","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1002\/cpt.597","article-title":"Clinical pharmacogenetics implementation consortium guideline (CPIC) for CYP2D6 and CYP2C19 genotypes and dosing of tricyclic antidepressants: 2016 update","volume":"102","author":"Hicks","year":"2017","journal-title":"Clin. Pharmacol. Ther."},{"key":"B35","doi-asserted-by":"publisher","first-page":"41","DOI":"10.2217\/pme-2021-0088","article-title":"Interventional cardiologists' attitudes towards pharmacogenetic testing and impact on antiplatelet prescribing decisions","volume":"19","author":"Hoffecker","year":"2022","journal-title":"Per Med."},{"key":"B36","doi-asserted-by":"publisher","first-page":"183","DOI":"10.1097\/FPC.0000000000000568","article-title":"Feasibility of pharmacogenetic-guided selection of postoperative analgesics in gynecologic surgery patients: a prospective, randomized, pilot study","volume":"35","author":"Hoffecker","year":"2025","journal-title":"Pharmacogenet Genomics"},{"key":"B37","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1002\/ajmg.c.31391","article-title":"PG4KDS: a model for the clinical implementation of pre-emptive pharmacogenetics","author":"Hoffman","year":"2014","journal-title":"Am. J. Med. Genet. C Semin. Med. Genet."},{"key":"B38","doi-asserted-by":"publisher","first-page":"167","DOI":"10.18865\/ed.30.S1.167","article-title":"Participatory genomic testing can effectively disseminate cardiovascular pharmacogenomics concepts within federally qualified health centers: a feasibility study","volume":"30","author":"Johnson","year":"2020","journal-title":"Ethn. Dis."},{"key":"B39","doi-asserted-by":"publisher","first-page":"1157","DOI":"10.1056\/NEJMra035092","article-title":"Developmental pharmacology--drug disposition, action, and therapy in infants and children","volume":"349","author":"Kearns","year":"2003","journal-title":"N. Engl. J. Med."},{"key":"B40","volume-title":"Pharmacogenetics","year":"2026"},{"key":"B41","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1016\/j.tips.2016.11.007","article-title":"Implementing precision medicine: the ethical challenges","volume":"38","author":"Korngiebel","year":"2017","journal-title":"Trends Pharmacol. Sci."},{"key":"B42","doi-asserted-by":"publisher","first-page":"82","DOI":"10.1186\/s40246-024-00648-y","article-title":"A qualitative approach to assess the opinion of physicians about the challenges and prospects of pharmacogenomic testing implementation in clinical practice in Greece","volume":"18","author":"Koufaki","year":"2024","journal-title":"Hum. Genomics"},{"key":"B43","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1186\/s12885-022-09171-6","article-title":"Preemptive pharmacogenetic testing to guide chemotherapy dosing in patients with gastrointestinal malignancies: a qualitative study of barriers to implementation","volume":"22","author":"Lau-Min","year":"2022","journal-title":"BMC Cancer"},{"key":"B44","doi-asserted-by":"publisher","first-page":"959","DOI":"10.1002\/cpt.2526","article-title":"Clinical pharmacogenetics implementation consortium guideline for CYP2C19 genotype and clopidogrel therapy: 2022 update","volume":"112","author":"Lee","year":"2022","journal-title":"Clin. Pharmacol. Ther."},{"key":"B45","doi-asserted-by":"publisher","first-page":"2467","DOI":"10.1111\/cts.13672","article-title":"Healthcare professionals' and consumers' knowledge, attitudes, perspectives, and education needs in oncology pharmacogenomics: a systematic review","volume":"16","author":"Lim","year":"2023","journal-title":"Clin. Transl. Sci."},{"key":"B46","doi-asserted-by":"publisher","first-page":"101","DOI":"10.1002\/cpt.2079","article-title":"A tutorial for pharmacogenomics implementation through end-to-end clinical decision support based on ten years of experience from PREDICT","volume":"109","author":"Liu","year":"2021","journal-title":"Clin. Pharmacol. Ther."},{"key":"B47","doi-asserted-by":"publisher","first-page":"253","DOI":"10.1016\/j.jmoldx.2021.11.008","article-title":"Targeted genotyping in clinical pharmacogenomics: what is missing?","volume":"24","author":"Lopes","year":"2022","journal-title":"J. Mol. Diagn"},{"key":"B48","doi-asserted-by":"publisher","first-page":"e13692","DOI":"10.1111\/cts.13692","article-title":"Feasibility of preemptive pharmacogenetic testing and improvement of medication treatment satisfaction among medically underserved patients","volume":"17","author":"Lteif","year":"2024","journal-title":"Clin. Transl. Sci."},{"key":"B49","doi-asserted-by":"publisher","first-page":"502","DOI":"10.1002\/cpt.630","article-title":"The pharmacogenomics research network translational pharmacogenetics program: outcomes and metrics of pharmacogenetic implementations across diverse healthcare systems","volume":"102","author":"Luzum","year":"2017","journal-title":"Clin. Pharmacol. Ther."},{"key":"B50","doi-asserted-by":"publisher","first-page":"945352","DOI":"10.3389\/fmed.2022.945352","article-title":"Characterizing pharmacogenetic programs using the consolidated framework for implementation research: a structured scoping review","volume":"9","author":"McDermott","year":"2022","journal-title":"Front. Med. (Lausanne)"},{"key":"B51","doi-asserted-by":"publisher","first-page":"398","DOI":"10.1111\/ahg.12601","article-title":"Embedding pharmacogenetics into clinical practice to improve patient outcomes","volume":"89","author":"McDermott","year":"2025","journal-title":"Ann. Hum. Genet."},{"key":"B52","doi-asserted-by":"publisher","first-page":"1318","DOI":"10.1002\/cpt.2754","article-title":"Cost effectiveness of pharmacogenetic testing for drugs with clinical pharmacogenetics implementation consortium (CPIC) guidelines: a systematic review","volume":"112","author":"Morris","year":"2022","journal-title":"Clin. Pharmacol. Ther."},{"key":"B53","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s13012-018-0842-6","article-title":"Systematic review of the exploration, preparation, implementation, sustainment (EPIS) framework","volume":"14","author":"Moullin","year":"2019","journal-title":"Implement Sci."},{"key":"B54","doi-asserted-by":"publisher","first-page":"247","DOI":"10.3343\/alm.2024.0652","article-title":"Pharmacogenomic testing in the clinical laboratory: historical progress and future opportunities","volume":"45","author":"Moyer","year":"2025","journal-title":"Ann. Lab. Med."},{"key":"B55","doi-asserted-by":"publisher","first-page":"321","DOI":"10.1002\/cpt.2773","article-title":"Prescriber adoption of SLCO1B1 genotype-guided simvastatin clinical decision support in a clinical pharmacogenetics program","volume":"113","author":"Obeng","year":"2023","journal-title":"Clin. Pharmacol. Ther."},{"key":"B56","doi-asserted-by":"publisher","first-page":"106247","DOI":"10.1016\/j.cct.2020.106247","article-title":"Study design and implementation of the PRecision medicine in MEntal health care (PRIME care) trial","volume":"101","author":"Oslin","year":"2021","journal-title":"Contemp. Clin. Trials"},{"key":"B57","doi-asserted-by":"publisher","first-page":"151","DOI":"10.1001\/jama.2022.9805","article-title":"Effect of pharmacogenomic testing for drug-gene interactions on medication selection and remission of symptoms in major depressive disorder: the PRIME care randomized clinical trial","volume":"328","author":"Oslin","year":"2022","journal-title":"Jama"},{"key":"B58","doi-asserted-by":"publisher","first-page":"292","DOI":"10.1111\/cts.13449","article-title":"Identifying the prevalence of clinically actionable drug-gene interactions in a health system biorepository to guide pharmacogenetics implementation services","volume":"16","author":"Pasternak","year":"2023","journal-title":"Clin. Transl. Sci."},{"key":"B59","doi-asserted-by":"publisher","first-page":"101622","DOI":"10.1016\/j.gim.2025.101622","article-title":"Perceptions, knowledge, and attitudes toward genetics among psychiatric patients and their relatives: a systematic review and a meta-analysis","volume":"28","author":"Prudhomme","year":"2026","journal-title":"Genet. Med."},{"key":"B60","doi-asserted-by":"publisher","first-page":"87","DOI":"10.1038\/clpt.2011.371","article-title":"Operational implementation of prospective genotyping for personalized medicine: the design of the vanderbilt PREDICT project","volume":"92","author":"Pulley","year":"2012","journal-title":"Clin. Pharmacol. Ther."},{"key":"B61","doi-asserted-by":"publisher","first-page":"1721828","DOI":"10.3389\/fphar.2026.1721828","article-title":"Addressing genetic diversity and health inequities: RELIVAF's proposal for Latin American pharmacogenomic guidelines","volume":"17","author":"Qui\u00f1ones","year":"2026","journal-title":"Front. Pharmacol."},{"key":"B62","doi-asserted-by":"publisher","first-page":"e104311","DOI":"10.1136\/bmjopen-2025-104311","article-title":"Exploring patient and professional perspectives on implementing pharmacogenomic testing in the UK primary care setting and estimating the cost-effectiveness: a mixed-methods study protocol","volume":"15","author":"Qureshi","year":"2025","journal-title":"BMJ Open"},{"key":"B63","doi-asserted-by":"publisher","first-page":"e64","DOI":"10.1331\/JAPhA.2011.11543","article-title":"Integrating pharmacogenomics into pharmacy practice via medication therapy management","volume":"51","author":"Reiss","year":"2011","journal-title":"J. Am. Pharm. Assoc."},{"key":"B64","doi-asserted-by":"publisher","first-page":"1095","DOI":"10.1002\/cpt.1304","article-title":"Clinical pharmacogenetics implementation consortium guideline for thiopurine dosing based on TPMT and NUDT15 genotypes: 2018 update","volume":"105","author":"Relling","year":"2019","journal-title":"Clin. Pharmacol. Ther."},{"key":"B65","doi-asserted-by":"publisher","first-page":"1191","DOI":"10.2217\/pgs-2020-0066","article-title":"The inclusion of health data standards in the implementation of pharmacogenomics systems: a scoping review","volume":"21","author":"Roosan","year":"2020","journal-title":"Pharmacogenomics"},{"key":"B66","doi-asserted-by":"publisher","first-page":"317","DOI":"10.1038\/clpt.2013.105","article-title":"Clinical pharmacogenetics implementation consortium guidelines for CYP2C19 genotype and clopidogrel therapy: 2013 update","volume":"94","author":"Scott","year":"2013","journal-title":"Clin. Pharmacol. Ther."},{"key":"B67","doi-asserted-by":"publisher","first-page":"52","DOI":"10.1089\/omi.2020.0178","article-title":"What do students in pharmacy and medicine think about pharmacogenomics and personalized medicine education? Awareness, attitudes, and perceptions in Malaysian health sciences","volume":"25","author":"Siamoglou","year":"2021","journal-title":"OMICS"},{"key":"B68","doi-asserted-by":"publisher","first-page":"436","DOI":"10.1177\/07067437221140383","article-title":"Pharmacogenomic testing for major depression: a qualitative study of the perceptions of people with lived experience and professional stakeholders","volume":"68","author":"Slomp","year":"2023","journal-title":"Can. J. Psychiatry"},{"key":"B69","doi-asserted-by":"publisher","first-page":"e13837","DOI":"10.1111\/cts.13837","article-title":"Pharmacogenetic testing in primary care could bolster depression treatment: a value proposition","volume":"17","author":"Sperber","year":"2024","journal-title":"Clin. Transl. Sci."},{"key":"B70","doi-asserted-by":"publisher","first-page":"347","DOI":"10.1016\/S0140-6736(22)01841-4","article-title":"A 12-gene pharmacogenetic panel to prevent adverse drug reactions: an open-label, multicentre, controlled, cluster-randomised crossover implementation study","volume":"401","author":"Swen","year":"2023","journal-title":"Lancet"},{"key":"B71","doi-asserted-by":"publisher","first-page":"191","DOI":"10.1097\/FPC.0000000000000413","article-title":"Patient insights on features of an effective pharmacogenomics patient portal","volume":"30","author":"Truong","year":"2020","journal-title":"Pharmacogenet Genomics"},{"key":"B72","doi-asserted-by":"publisher","first-page":"371","DOI":"10.1111\/cts.13154","article-title":"Multisite evaluation of institutional processes and implementation determinants for pharmacogenetic testing to guide antidepressant therapy","volume":"15","author":"Tuteja","year":"2022","journal-title":"Clin. Transl. Sci."},{"key":"B73","doi-asserted-by":"publisher","first-page":"915","DOI":"10.2217\/pgs-2023-0185","article-title":"Pre-emptive pharmacogenomics implementation among polypharmacy patients 65 years old and older: a clinical pilot","volume":"24","author":"Uber","year":"2023","journal-title":"Pharmacogenomics"},{"key":"B74","doi-asserted-by":"publisher","first-page":"1763975","DOI":"10.3389\/fpubh.2026.1763975","article-title":"Pre-emptive pharmacogenetic testing in Italy: a review of evidence and multidisciplinary consensus on key priorities for implementation","volume":"14","author":"Valz Gris","year":"2026","journal-title":"Front. Public Health"},{"key":"B75","doi-asserted-by":"publisher","first-page":"341","DOI":"10.1002\/cpt.602","article-title":"Implementing pharmacogenomics in Europe: design and implementation strategy of the ubiquitous pharmacogenomics consortium","volume":"101","author":"van der Wouden","year":"2017","journal-title":"Clin. Pharmacol. Ther."},{"key":"B76","doi-asserted-by":"publisher","first-page":"1108","DOI":"10.1002\/phar.2463","article-title":"DPYD and UGT1A1 pharmacogenetic testing in patients with gastrointestinal malignancies: an overview of the evidence and considerations for clinical implementation","volume":"40","author":"Varughese","year":"2020","journal-title":"Pharmacotherapy"},{"key":"B77","doi-asserted-by":"publisher","first-page":"859846","DOI":"10.3389\/fonc.2022.859846","article-title":"Implementing pharmacogenetic testing in gastrointestinal cancers (IMPACT-GI): study protocol for a pragmatic implementation trial for establishing DPYD and UGT1A1 screening to guide chemotherapy dosing","volume":"12","author":"Varughese","year":"2022","journal-title":"Front. Oncol."},{"key":"B78","doi-asserted-by":"publisher","first-page":"518","DOI":"10.1186\/s12888-020-02919-z","article-title":"Primary care and mental health providers' perceptions of implementation of pharmacogenetics testing for depression prescribing","volume":"20","author":"Vest","year":"2020","journal-title":"BMC Psychiatry"},{"key":"B79","doi-asserted-by":"publisher","first-page":"1270","DOI":"10.1176\/appi.ps.20220537","article-title":"Providers' use of pharmacogenetic testing to inform antidepressant prescribing: results of qualitative interviews","volume":"74","author":"Vest","year":"2023","journal-title":"Psychiatr. Serv."},{"key":"B80","doi-asserted-by":"publisher","first-page":"589","DOI":"10.1176\/appi.ps.20240080","article-title":"The perceived value of pharmacogenetic testing in depression treatment: mixed-methods results from the PRIME care study","volume":"76","author":"Vest","year":"2025","journal-title":"Psychiatr. Serv."},{"key":"B81","doi-asserted-by":"publisher","first-page":"513","DOI":"10.1080\/14622416.2025.2571387","article-title":"Characterizing models for delivery of pharmacogenomic testing: a scoping review","volume":"26","author":"Waheed","year":"2025","journal-title":"Pharmacogenomics"},{"key":"B82","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1186\/1748-5908-9-39","article-title":"Expert recommendations for implementing change (ERIC): protocol for a mixed methods study","volume":"9","author":"Waltz","year":"2014","journal-title":"Implement Sci."},{"key":"B83","doi-asserted-by":"publisher","first-page":"2520","DOI":"10.1056\/NEJMoa2111749","article-title":"Ticagrelor versus clopidogrel in CYP2C19 loss-of-function carriers with stroke or TIA","volume":"385","author":"Wang","year":"2021","journal-title":"N. Engl. J. Med."},{"key":"B84","doi-asserted-by":"publisher","first-page":"809","DOI":"10.1016\/j.ajhg.2024.04.002","article-title":"Aspiring toward equitable benefits from genomic advances to individuals of ancestrally diverse backgrounds","volume":"111","author":"Wang","year":"2024","journal-title":"Am. J. Hum. Genet."},{"key":"B85","doi-asserted-by":"publisher","first-page":"131","DOI":"10.1016\/j.ghrp.2026.06.005","article-title":"Design and method considerations for equity-centered implementation science and practice: a PEDALs approach","volume":"11","author":"Wang","year":"2026","journal-title":"Glob. Health Res. Policy"},{"key":"B86","doi-asserted-by":"publisher","first-page":"1369","DOI":"10.1186\/s12885-024-13122-8","article-title":"DPYD genotype-guided dose personalisation for fluoropyrimidine-based chemotherapy prescribing in solid organ cancer patients in Australia: genescreen 5-FU study protocol","volume":"24","author":"White","year":"2024","journal-title":"BMC Cancer"},{"key":"B87","doi-asserted-by":"publisher","first-page":"188","DOI":"10.1016\/j.japh.2022.09.002","article-title":"Implementing comprehensive pharmacogenomics in a community hospital-associated primary care setting","volume":"63","author":"Wick","year":"2023","journal-title":"J. Am. Pharm. Assoc."},{"key":"B88","doi-asserted-by":"publisher","first-page":"862","DOI":"10.3390\/genes15070862","article-title":"Overcoming barriers: strategies for implementing pharmacist-led pharmacogenetic services in Swiss clinical practice","volume":"15","author":"Wiss","year":"2024","journal-title":"Genes (Basel)"},{"key":"B89","doi-asserted-by":"publisher","first-page":"211","DOI":"10.1097\/FTD.0000000000001243","article-title":"Implementation and evaluation strategies for pharmacogenetic testing in hospital settings: a scoping review","volume":"47","author":"Wu","year":"2024","journal-title":"Ther. Drug Monit."},{"key":"B90","doi-asserted-by":"publisher","first-page":"133","DOI":"10.2217\/pgs-2023-0193","article-title":"Workforce readiness for pharmacogenomics and key elements for sustainment within the veterans health administration","volume":"25","author":"Wu","year":"2024","journal-title":"Pharmacogenomics"}],"container-title":["Frontiers in Pharmacology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fphar.2026.1906466\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,11]],"date-time":"2026-09-11T14:16:29Z","timestamp":1789136189000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fphar.2026.1906466\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9,11]]},"references-count":90,"alternative-id":["10.3389\/fphar.2026.1906466"],"URL":"https:\/\/doi.org\/10.3389\/fphar.2026.1906466","relation":{},"ISSN":["1663-9812"],"issn-type":[{"value":"1663-9812","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,9,11]]},"article-number":"1906466"}}